I'd like to offer a suggestion. I think there are a number of ways to deal with that. We see this approach in place in other jurisdictions. A good example is right next door to us, the U.S. FDA. The FDA, before licensing any product, does an open-panel review hearing that allows for citizen engagement. It allows for the companies to sit there and answer questions as well, to be questioned by the committee and the panel in a full public environment. We see public hearings as well.
Our hope is to allow—because remember, at the end of the day, cost effectiveness—Everyone talks about the science of health technology assessment. It's not science. At the end of the day, it's still opinion, and it's opinion of a very select few people in terms of what value is. Our question on that one is to do that in public, have a public meeting. Yes, there may be a big crowd out there, but let the crowd hear what the view is, hear what the debates are, the positives and negatives, and allow for perhaps selected input into that discussion, into that framework.
At the end of the day, it's going to be those people who are most affected, whether they be physicians, pharmacists, patients, or even the manufacturers that have done the research and development to bring it there to be able to inform a group. We find it's particularly important, especially when you're dealing with unmet needs and rare diseases, where there is no 30- to 40-year history in terms of the disease treatment cycle—